Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1971 1
1973 1
1974 2
1975 1
1978 1
1980 2
1982 1
1984 1
1986 1
1989 1
1992 1
1993 2
1998 1
1999 1
2005 1
2006 1
2008 1
2010 4
2011 3
2012 2
2013 1
2014 1
2015 3
2016 5
2017 4
2018 5
2019 7
2020 5
2021 8
2022 9
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, Beck LA, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman SR, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira HD, Lin CY, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes JM, DeLozier AM, Nunes FP, Paller AS. Simpson E, et al. Among authors: milutinovic m. J Am Acad Dermatol. 2020 Sep;83(3):839-846. doi: 10.1016/j.jaad.2020.04.104. Epub 2020 Apr 25. J Am Acad Dermatol. 2020. PMID: 32344071
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. Among authors: milutinovic m. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Free article. Clinical Trial.
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Bissonnette R, et al. Among authors: milutinovic m. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514. doi: 10.1111/jdv.14878. Epub 2018 Mar 22. J Eur Acad Dermatol Venereol. 2018. PMID: 29444376 Free PMC article. Clinical Trial.
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, Guttman-Yassky E, Thaci D, Simpson EL, Harris JE, Krueger J, Myers DE, Gamelli A, Milutinovic M, Parneix A, Crawford JM, Hildebrand JS, Munoz B, Paller AS. Abuabara K, et al. Among authors: milutinovic m. J Am Acad Dermatol. 2023 Aug;89(2):345-347. doi: 10.1016/j.jaad.2022.08.065. Epub 2022 Dec 13. J Am Acad Dermatol. 2023. PMID: 36521798 No abstract available.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
Bissonnette R, Eichenfield LF, Simpson E, Thaçi D, Kabashima K, Thyssen JP, Guttman-Yassky E, Nunes FP, Gamalo M, Ahmad F, Kuligowski M, Sun K, Pipper C, Christensen AW, D'Angelo P, Milutinovic M, Guettner A, Silverberg JI. Bissonnette R, et al. Among authors: milutinovic m. J Eur Acad Dermatol Venereol. 2023 May;37(5):976-983. doi: 10.1111/jdv.18881. Epub 2023 Feb 25. J Eur Acad Dermatol Venereol. 2023. PMID: 36652273 Review.
MicroRNA expression as a diagnostic parameter in early endometrial cancer.
Blagojević S, Andrić B, Jovankić J, Milutinović M, Nikodijević D, Arsenijević P, Cvetković D. Blagojević S, et al. Among authors: milutinovic m. Int J Gynecol Cancer. 2023 Sep 4;33(9):1394-1401. doi: 10.1136/ijgc-2023-004579. Int J Gynecol Cancer. 2023. PMID: 37541686
88 results